Myriad Genetics | MYGN - Debt


Myriad Genetics reported $59.3M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
Agilent USD 3.36B 1000K Mar/2026
Becton, Dickinson and Co. USD 16.81B 471M Jun/2026
Bio-Rad Laboratories USD 1.37B 7.8M Jun/2026
Bruker USD 1.82B 153.5M Jun/2026
Danaher USD 26.48B 76M Sep/2026
Illumina USD 2.54B 9M Mar/2026
J&J USD 49.04B 5.95B Jun/2026
Mettler Toledo International USD 2.11B 116.68M Jun/2026
Myriad Genetics USD 59.3M 19.7M Mar/2025
OraSure Technologies USD 782K 465K Jun/2024
Pacific Biosciences Of California USD 892.24M 653K Dec/2023
Quest Diagnostics USD 6.38B 23M Jun/2026
Quidel USD 3.08B 200.7M Jun/2026
Repligen USD 555.6M 135.35M Sep/2026
Revvity USD 2.63B 707.45M Sep/2026
Standard Biotools USD 28.09M 1.4M Jun/2026
Thermo Fisher Scientific USD 42.55B 612M Jun/2026
Veracyte USD 40.11M 774K Jun/2026
Waters USD 5.45B 116M Jun/2026